Brokerage firm KeyBanc Upgrades its rating on PRA Health Sciences Inc(NASDAQ:PRAH). The shares have been rated Overweight. Previously, the analysts had a Sector Weight rating on the shares. The rating by KeyBanc was issued on Jun 13, 2016.
In a different note, On May 4, 2016, Citigroup said it Upgrades its rating on PRA Health Sciences Inc. In the research note, the firm Raises the price-target to $51.00 per share. The shares have been rated ‘Buy’ by the firm. On Mar 28, 2016, SunTrust Robinson Humphrey said it Upgrades its rating on PRA Health Sciences Inc. In the research note, the firm Raises the price-target to $47.00 per share. The shares have been rated ‘Buy’ by the firm.
PRA Health Sciences Inc (PRAH) shares turned negative on Fridays trading session with the shares closing down -2 points or -4.56% at a volume of 6,87,734. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $44.405. The peak price level was also seen at $44.405 while the days lowest was $41.77. Finally the shares closed at $41.9. The 52-week high of the shares is $51.35 while the 52-week low is $33. According to the latest information available, the market cap of the company is $2,537 M.
PRA Health Sciences Inc(PRAH) last announced its earnings results on Apr 27, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $372.32M. Analysts had an estimated revenue of $372.21M. Earnings per share were $0.55. Analysts had estimated an EPS of $0.53.
Several Insider Transactions has been reported to the SEC. On May 10, 2016, Linda Baddour (Executive VP & CFO) sold 92,308 shares at $46.70 per share price.Also, On Mar 10, 2016, Colin Shannon (President & CEO) sold 77,019 shares at $42.26 per share price.
PRA Health Sciences Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development including oncology central nervous system inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services which includes Phase IIb through III product registration trials and Phase IV trials inclusive of post-marketing commitments and registries; Strategic Solutions which provides Embedded Solutions and functional outsourcing services and Early Development Services which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.